Dr. Reddy's Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 1
Author: Deven Choksey

Keep track of all breaking news and updates on Dr. Reddy's Laboratories Ltd. from all sources in a single place.

Dr. Reddy's Laboratories Ltd.

19 Sep 2025

1301.90

-1.50%

SAST

Dr Reddys Laboratories Ltd - 500124 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for VSD Family Trust & PACs

pdf

Dr. Reddy's Laboratories Ltd.

19 Sep 2025

1301.90

-1.50%

SAST

Dr Reddys Laboratories Ltd - 500124 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for VSD Family Trust & PACs

pdf

Dr. Reddy's Laboratories Ltd.

18 Sep 2025

1301.90

-1.50%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

pdf

Dr. Reddy's Laboratories Ltd.

17 Sep 2025

1301.90

-1.50%

India's bulk drug makers start preparing for Ozempic patent expiry

Business Standard

From local giants Dr Reddy's Laboratories Ltd. to suppliers like Macleods Pharmaceuticals Ltd., Indian firms are preparing to make bulk drugs

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr Reddy's launches Tegoprazan for treatment of acid-related disorders in Indian market

Business Line | 16 Sep 2025 1 more

Dr. Reddy's Laboratories Ltd.

16 Sep 2025

1301.90

-1.50%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

pdf

Dr. Reddy's Laboratories Ltd.

15 Sep 2025

1301.90

-1.50%

Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations

Business Standard

Dr Reddy's shares fell on Monday after the USFDA issued a Form 483 with five observations at its Hyderabad plant inspection

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

15 Sep 2025

1301.90

-1.50%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

Allotment of Employee Stock Options

pdf

Dr. Reddy's Laboratories Ltd.

13 Sep 2025

1301.90

-1.50%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations …

BSE India

Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015

pdf

Dr. Reddy's Laboratories Ltd.

11 Sep 2025

1301.90

-1.50%

Dr Reddy's signs pact with J&J to acquire vertigo treatment brand

Business Standard

Dr Reddy's Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets. Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy's Laboratories said in a statement. Dr Reddy's acquisition of the brand reflects a steady advancement in the company's efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of CNS portfolio, said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories. "Backed by our strong market access, we intend to extend the reach of Stugeron and its associated products across 18 key markets in the ..

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr Reddy's enters anti-vertigo segment with acquisition of Stugeron from Johnson & Johnson

Business Line | 11 Sep 2025 1 more

Dr. Reddy's Laboratories Ltd.

11 Sep 2025

1301.90

-1.50%

Stock Flash

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Dr. Reddy’s Laboratories Ltd. has entered into a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire the STUGERON® brand along with its leading local brands STUGERON® FORTE and STUGERON® PLUS.

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Is Dr. Reddy's Laboratories Ltd. worth buying?

523 Votes:

Buy 77.82%

Sell 12.43%

Hold 9.75%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf